Straits Times Index
3,292.45 -0.24 (-0.01%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,207.13 +444.10 (+2.50%) FTSE 100
8,154.89 +33.65 (+0.41%) Bitcoin USD
57,806.45 +882.84 (+1.55%) CMC Crypto 200
1,266.00 -4.74 (-0.37%)
Novo Nordisk A/S (0TDD.L)
| Previous close | 129.07 |
| Open | 132.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 125.30 - 132.88 |
| 52-week range | 68.37 - 142.93 |
| Volume | |
| Avg. volume | 22,405 |
| Market cap | 2.899B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 0.42 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024
Bagsværd, Denmark, 2 May 2024 - financial report for the period 1 January 2024 to 31 March 2024 Operating profit increased by 27% in Danish kroner and by 30% at constant exchange rates (CER) to DKK 31.8 billion. Sales in North America Operations increased by 34% in Danish kroner (35% at CER). Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years. Sales in International Operations increased by 8% in Danish kroner (11% at CER).Sales within Diabetes
- GlobeNewswire
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 1 May 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme init
- GlobeNewswire
Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024
Bagsværd, Denmark, 26 April 2024 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Referring to Company Announcement no 32/2024 dated 24 April 2024, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 26 April 2024. Number of
